Sun Pharma’s Fresh OAI Tag Is a Reminder That USFDA Risk Is Never Fully Priced Out

shares slipped about 3% after the US FDA classified its Baska, Gujarat facility as “Official Action Indicated” (OAI) following a September inspection. The plant can continue supplying already‑approved products, but the status allows the regulator to withhold new approvals or supplements tied to this site until all compliance gaps are fixed.​ OAI is not unfamiliar territory for Sun: Halol has already been under OAI and import alert, and Dadra too has drawn adverse regulatory attention, effectively ring‑fencing a chunk of its US generics manufacturing base. While management has consistently reiterated its commitment to remediation and CGMP upgrades, each fresh OAI reinforces the overhang that US compliance is a structural, not episodic, challenge for the group.​ From an earnings perspective, the immediate hit from Baska looks manageable, given Sun’s diversified US portfolio and growing specialty franchise, but the medium‑term risk lies in slower product flow and higher remediation costs. For investors who have treated Sun as a relatively “defensive” large-cap pharma bet, the latest classification is a reminder that regulatory risk deserves a more explicit discount in valuations until there is visible, sustained closure on key plants. Source: The Hindu No Recommendations